Yucai Wang, Ph.D. is a Professor at the Division of Life Sciences and Medicine, University of Science and Technology of China (USTC) and Vice President of Hefei RNAlfa Biotech Co., Ltd. He received his B.S. and Ph.D. degrees from USTC in 2005 and 2010, respectively, and pursued postdoctoral training in biomedical engineering and chemistry at Washington University at Saint Louis, Georgia Institute of Technology, and the University of Chicago. In 2015, he returned to USTC as a faculty member through the “Young Thousand Talents Plan” and was later awarded the National Natural Science Foundation of China (NSFC) for Distinguished Young Scholars in 2020.

His research focuses on nanomedicine, biomaterials, and mRNA therapeutics, with an emphasis on understanding and overcoming in vivo delivery barriers. He has published over 100 peer-reviewed papers in top journals including Nature Nanotechnology, Nature Materials, and Nature Biomedical Engineering. In addition to his academic contributions, Dr. Wang has actively promoted the clinical translation of mRNA technologies through RNAlfa Biotech, which has obtained multiple IND approvals for mRNA vaccines and therapeutics.

Outside of research, he enjoys soccer, gourmet food, traveling, and video games. He believes in perseverance as the driving force of scientific discovery — “Though the road is long, step by step it will be reached; though the task is difficult, persistence will bring success.” He also emphasizes that scientific innovation should be closely aligned with industrial needs, striving to transform research into real-world applications that benefit society.